Core Insights - TScan Therapeutics, Inc. will host a virtual key opinion leader event to discuss updated data from the ALLOHA Phase 1 trial and future market opportunities for its heme program [1][2] - The event will include a review of two-year relapse data from the ongoing ALLOHA Phase 1 trial evaluating TSC-101 in patients with hematologic malignancies [2] - The company has implemented an improved commercial-ready manufacturing process for the ALLOHA Phase 1 trial, which will be utilized in the upcoming pivotal trial set to begin in Q2 2026 [2] Company Overview - TScan Therapeutics is a clinical-stage biotechnology company focused on developing T cell receptor-engineered T cell therapies for cancer treatment [4] - The lead therapy candidate is aimed at preventing relapse in patients with hematologic malignancies following allogeneic hematopoietic cell transplantation [4] - The company is also developing multiple TCR-T therapy candidates for solid tumors and exploring novel targets in T cell-mediated autoimmune disorders through its TargetScan platform [4]